Clinical-stage precision health company EXACT Therapeutics AS (EXACT-Tx) (Euronext Growth:EXTX) has been granted a new patent in the UK relating to Acoustic Cluster Therapy (ACT), a technology platform for targeted therapeutic enhancement, the company announced on Tuesday.

The patent from the Intellectual Property Office covers EXACT-Tx's microbubble/microdroplet formulation (PS101) and its co-administration with a range of pharmaceutical agents for ultrasound-mediated drug targeting in the treatment of infections. This strengthens EXACT-Tx's mission to enhance the therapeutic outcome of the standard of care across drug classes.

ACT is a proprietary formulation consisting of microbubbles and microdroplets activated by ultrasound to enhance the targeted delivery of therapeutic agents. The ACT platform has demonstrated therapeutic enhancement in preclinical models for oncology, including pancreatic, breast, colon and prostate cancers, as well as blood-brain barrier penetration. While the initial focus is on oncology, the ACT platform holds potential for application in other therapeutic areas and product classes.